Cold-adapted equine influenza viruses

Abstract

The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus or other infectious agents utilizing the claimed therapeutic compositions. Such methods include using a therapeutic composition as a vaccine to generate a protective immune response in an animal prior to exposure to an infectious agent, as well as using a therapeutic composition as a treatment for an animal that has been recently infected with an infectious agent leading to respiratory disease, or is likely to be subsequently exposed to such an agent in a few days whereby the therapeutic composition reduces such respiratory disease, even in the absence of antibody-mediated immunity. The present invention also provides methods to produce cold-adapted equine influenza viruses, and reassortant influenza A viruses having at least one genome segment of an equine influenza virus generated by cold-adaptation.

1 - 16 . (canceled)  
   
   
       17 . A method to treat an animal for respiratory disease comprising administering to said animal a therapeutic composition comprising a virus selected from the group consisting of: (a) a cold-adapted equine influenza virus; and (b) a reassortant influenza A virus comprising at least one genome segment of an equine influenza virus generated by cold-adaptation, said equine influenza virus having an identifying phenotype selected from the group consisting of cold-adaptation, temperature sensitivity, dominant interference, and attenuation, wherein said equine influenza virus genome segment confers at least one of said identifying phenotypes to said reassortant virus.  
   
   
       18 . The method of  claim 17 , wherein said respiratory disease is caused by viral or bacterial infection or a combination thereof.  
   
   
       19 . The method of  claim 17 , wherein said respiratory disease is caused by influenza.  
   
   
       20 . The method of  claim 17 , wherein said animal is an equid.  
   
   
       21 . The method of  claim 17 , wherein said therapeutic composition comprises from about 10 7  TCID 50  units to about 10 8  TCID 50  units of said virus.  
   
   
       22 . The method of  claim 17 , wherein said therapeutic composition treats an equid for respiratory disease that exhibits nasal discharge as the major clinical sign of infection.  
   
   
       23 . The method of  claim 17 , wherein said therapeutic composition treats an equid from about 3 months to about 2 years of age against nasal discharge.  
   
   
       24 . The method of  claim 17 , wherein said therapeutic composition treats an equid for respiratory disease in which major clinical signs of disease are reduced within about 7 days.  
   
   
       25 . A method to treat an animal for respiratory disease comprising administering to said animal a therapeutic composition comprising a virus selected from the group consisting of: (a) a cold-adapted equine influenza virus having a dominant interference phenotype; and (b) a reassortant influenza A virus comprising a portion of an equine influenza virus genome conferring cold-adaptation and dominant interference phenotypes, wherein said therapeutic composition exhibits non-specific interference.  
   
   
       26 . The method of  claim 25 , wherein said animal is an equid.  
   
   
       27 . The method of  claim 25 , wherein said therapeutic composition inhibits viral or bacterial infection, or a combination thereof.  
   
   
       28 . The method of  claim 25 , wherein said therapeutic composition inhibits secondary viral or bacterial infection, or a combination thereof.  
   
   
       29 . The method of  claim 25 , wherein said respiratory disease is equine influenza, and wherein said therapeutic composition exhibits dominant interference.  
   
   
       30 . The method of  claim 25 , wherein said therapeutic composition treats an equid for respiratory disease that exhibits nasal discharge and fever as early signs of infection.  
   
   
       31 . The method of  claim 25 , wherein said therapeutic composition treats an equid for respiratory disease that exhibits nasal discharge as a late stage sign of infection.  
   
   
       32 . The method of  claim 25 , wherein said therapeutic composition treats an equid for respiratory disease in which major clinical signs of disease are reduced within about 7 days.  
   
   
       33 . The method of  claim 26 , wherein said therapeutic composition treats an equid for respiratory disease in which major clinical signs of disease are reduced within about 7 days, and race training of the equid can resume within about 10 days of treatment.  
   
   
       34 . The method of  claim 25 , wherein said therapeutic composition comprises from about 10 7  TCID 50  units to about 10 8  TCID 50  units of said virus.  
   
   
       35 . The method of  claim 25 , wherein said therapeutic composition has an anti-viral effect.